In her early career, Dianne was an educator and L&D specialist, experienced in curriculum and program development & delivery in the field of English as a Second and Foreign Language. Later, she worked as a business manager in the pharmaceutical and medical devices industries across a broad range of functions, including customer relationship and supply chain management.
As a foundation member of the Australian National eHealth Transition Authority’s Supply Chain Reference group, Dianne represented pharmaceutical companies contributing to the implementation of global standards across Australian healthcare supply chains. Her interest in haemochromatosis patient advocacy started in 2010 when she began researching patient advocacy organisations in Australia and was awarded a Doctor of Business Administration by the University of Wollongong in 2017 for research on ‘not for profit’ health consumer organisations.
Dianne says, “I believe in the importance of knowing an individual’s risk of iron overload and its impact if not detected and treated early, and am a strong advocate for population screening to prevent harm from haemochromatosis. Fortunately, C282Y mutations were detected early in my family by chance during genetic testing associated with genome mapping activity in the 1990s.”
Dianne joined Haemochromatosis Australia as a volunteer advocate and served as national president from 2016 to 2021. She has been a Trustee of Haemochromatosis International since 2017 and president since 2019.